Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1964 2
1965 1
1966 3
1967 2
1968 1
1969 2
1971 1
1974 5
1975 4
1976 6
1977 4
1978 11
1979 5
1980 6
1981 5
1982 4
1983 6
1984 8
1985 11
1986 6
1987 6
1988 16
1989 13
1990 13
1991 13
1992 16
1993 9
1994 14
1995 11
1996 13
1997 21
1998 15
1999 12
2000 20
2001 21
2002 25
2003 29
2004 22
2005 35
2006 36
2007 45
2008 37
2009 51
2010 51
2011 69
2012 86
2013 86
2014 99
2015 118
2016 112
2017 118
2018 107
2019 103
2020 129
2021 133
2022 129
2023 113
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

1,834 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticu …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations. ...
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal …
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A. Gangat N, et al. Br J Haematol. 2020 Oct;191(2):152-170. doi: 10.1111/bjh.16576. Epub 2020 Mar 20. Br J Haematol. 2020. PMID: 32196650 Free article. Review.
The ensuing disrupted interactions amongst the megakaryocytes, osteoblasts, endothelium, stromal cells and myofibroblasts within the bone marrow culminate in the development of fibrosis and osteosclerosis. Presently, prognostic assessment tools for primary myelofibrosis …
The ensuing disrupted interactions amongst the megakaryocytes, osteoblasts, endothelium, stromal cells and myofibroblasts within the bone ma …
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M. Garmezy B, et al. Blood Rev. 2021 Jan;45:100691. doi: 10.1016/j.blre.2020.100691. Epub 2020 Apr 7. Blood Rev. 2021. PMID: 32354563 Review.
Although understanding of the pathogenesis and molecular biology of primary myelofibrosis continues to improve, treatment options are limited, and several biological features remain unexplained. ...
Although understanding of the pathogenesis and molecular biology of primary myelofibrosis continues to improve, treatment opti …
Momelotinib: First Approval.
Keam SJ. Keam SJ. Drugs. 2023 Dec;83(18):1709-1715. doi: 10.1007/s40265-023-01964-8. Drugs. 2023. PMID: 37989928 Review.
Morphology of myeloproliferative neoplasms.
Ng ZY, Fuller KA, Mazza-Parton A, Erber WN. Ng ZY, et al. Int J Lab Hematol. 2023 Jun;45 Suppl 2:59-70. doi: 10.1111/ijlh.14086. Epub 2023 May 21. Int J Lab Hematol. 2023. PMID: 37211431 Review.
The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, es …
The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosi …
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A. Guglielmelli P, et al. J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9. J Clin Oncol. 2018. PMID: 29226763 Free article.
Purpose To develop a prognostic system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. ...
Purpose To develop a prognostic system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clini …
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. Cervantes F, et al. Blood. 2009 Mar 26;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6. Blood. 2009. PMID: 18988864 Free article.
Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. ...
Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allog …
State-of-the-Art Review on Myelofibrosis Therapies.
Wang F, Qiu T, Wang H, Yang Q. Wang F, et al. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e350-e362. doi: 10.1016/j.clml.2021.11.007. Epub 2021 Nov 15. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34903489 Review.
Treating early-stage myelofibrosis.
Palandri F, Sabattini E, Maffioli M. Palandri F, et al. Ann Hematol. 2019 Feb;98(2):241-253. doi: 10.1007/s00277-018-3526-z. Epub 2018 Oct 20. Ann Hematol. 2019. PMID: 30343328 Review.
1,834 results